Discontinuation report PLAVIX
| Report ID | 100941 |
| Drug Identification Number | 02330555 |
| Brand name | PLAVIX |
| Common or Proper name | Plavix |
| Company Name | SANOFI-AVENTIS CANADA INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | CLOPIDOGREL |
| Strength(s) | 300MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 30 |
| ATC code | B01AC |
| ATC description | ANTITHROMBOTIC AGENTS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2020-11-30 |
| Actual discontinuation date | |
| Remaining supply date | 2020-11-30 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | email: CAINTERNET@sanofi.com Telephone: 1-800-265-7927 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v1 | 2019-12-11 | English | Compare |
| v2 | 2019-12-11 | French | Compare |
| v3 | 2019-12-11 | English | Compare |
| v4 | 2019-12-11 | French | Compare |
Showing 1 to 4 of 4